GLD Partners Acquires Seelos Therapeutics Assets, Advancing Ketamine and Trehalose Programs to Phase 3 Trials
Key Insights
GLD Partners (search), LP successfully acquired Seelos Therapeutics' late-stage ketamine and trehalose programs through a Chapter 11 bankruptcy process, positioning both assets for Phase 3 clinical development.
The ketamine program targets major depressive disorder (search) and neuropsychiatric conditions (search), with GLD planning confirmatory Phase 3 pivotal trials aligned with FDA guidance.
The trehalose program represents a disease-modifying therapy for rare neurodegenerative and lysosomal storage disorders (search), advancing to adaptive Phase 2/3 studies with orphan drug designation potential.
GLD Partners (search), LP announced the successful acquisition of select assets from Seelos Therapeutics, Inc. through a Chapter 11 bankruptcy process, securing two late-stage therapeutic programs with significant potential in central nervous system and rare disease treatments. The transaction, completed through a Section 363 sale in the U.S. Bankruptcy Court in the Southern District of New York, includes Seelos' ketamine and trehalose programs, both advancing toward Phase 3 clinical trials.
Strategic Acquisition Through Bankruptcy Process
Following its acquisition of Seelos' senior secured debt, GLD served as the stalking horse bidder and emerged as the successful acquirer. "Seelos' ketamine and trehalose assets align with our strategy of acquiring scientifically validated, late-stage programs that were undercapitalized but hold transformative potential," said Daniel Gordon, Managing Director of GLD Partners (search) LP.
The acquisition represents a capital-efficient approach to securing high-value therapeutic assets at an attractive valuation with strong upside potential, according to the company.
Ketamine Program for Major Depressive Disorder
The ketamine program is positioned as a CNS therapy for major depressive disorder (search) (MDD) and related neuropsychiatric conditions (search). Despite previous operational and clinical challenges, GLD emphasizes that the underlying science remains compelling. The company plans to initiate confirmatory Phase 3 pivotal trials aligned with FDA guidance, leveraging existing safety and efficacy data with enhanced study design and execution.
The global MDD therapeutics market presents substantial commercial opportunity, with Future Market Insights analysis projecting the market to exceed $15 billion annually by 2035. Ketamine-based treatments are expected to drive significant growth within this expanding market.
Trehalose for Rare Neurodegenerative Disorders
The trehalose program represents a disease-modifying therapy candidate for rare neurodegenerative and lysosomal storage disorders (search). GLD will progress trehalose into adaptive Phase 2/3 studies, supported by recent regulatory feedback and opportunities for orphan drug designation and expedited development.
Trehalose's rare disease applications operate within a multibillion-dollar space for rare disease treatments, where orphan drug frameworks and premium per-patient pricing have supported high-value therapeutic opportunities.
Enhanced Development Strategy
While prior trials of both programs faced operational and clinical challenges, GLD aims to advance both programs through late-stage development with enhancements to intellectual property and renewed focus on trial design and execution. The company's operational infrastructure and focused regulatory strategy are expected to enable efficient advancement toward patient impact.
"Merged into our existing biotech portfolio, these programs will benefit from GLD's focused regulatory strategy and execution discipline," Gordon noted. The assets not only offer stand-alone value but also strengthen GLD's existing portfolio of CNS and rare disease programs, enabling both clinical and commercial synergies.
Pipeline Acceleration and Value Inflection
With enhanced trial design and GLD's operational infrastructure, near-to mid-term value inflection points are expected from upcoming Phase 3 trials and regulatory milestones. "This transaction underscores our commitment to identifying underappreciated assets and executing the strategies needed to realize their full potential," Gordon added. "We're confident these programs can achieve meaningful clinical milestones and contribute lasting value across our life sciences portfolio."